Oncolytics Biotech Inc T.ONC

30 million for breast cancer trial

[spesestsemper]

So , if i heard from the fireside correctly today , they need 30 million to fund the next breast cancer trial . At theses levels that is approximately 30 million shares . They could exercise some of their options and help get the share price up with insider buying . They get it up enough past $3 , then maybe some warrants will get exercised . Between the options and the warrants , they wouldn't have to issue that many additional shares .  At any rate - higher the share price - less dilution . Nice to see some questions being asked today from the attendees , not like the previous fireside . Still wish they would just sell things outright . $500 million would be a win for everyone at this stage , in my opinion .




sec.gov/Archives/edgar/data/1129928/000110465924085444/tm2420730d2_suppl.htm#B_014





Date of Grant Number of Stock Options Granted Exercise Price (C$) Expiry Date August 15, 2023 777,500 2.76 August 15, 2028 September 11, 2023 25,000 3.05 September 11, 2028 December 8, 2023 1,342,900 1.91 December 8, 2028 January 5, 2024 45,000 1.76 January 5, 2029 January 22, 2024 15,000 1.62 January 22, 2029 May 28, 2024 250,000 1.53 May 28, 2029

As of the date hereof, we have 7,667,050 Common Share purchase warrants (the “2023 Warrants”) issued and outstanding. Each 2023 Warrant entitles the holder to purchase one common share at an exercise price of US$2.81 until August 8, 2028.

 

As of the date hereof, we have 536,693 Common Share purchase warrants (the “2023 Compensation Warrants”) issued and outstanding. Each 2023 Compensation Warrant entitles the holder to purchase one common share at an exercise price of US$2.25 until August 8, 2028.

 

[Noteable]

ONCY has $500 million in R&D write-offs and the potential of $US 5.89 Billion in peak annual sales for the 3rd line HR+/HER2- breast cancer alone, and with 13 years of FDA market exclusivity from the approval date of pelareorep. And then there are the PDAC, anal cancer,  TNBC and GI cancer indications as follow-on approvals.

[spesestsemper]

Thats all in the future . Right now we are worth about 100 million .  Don't get me wrong , I'll take a muttiple buillion dollar deal any time . Listen to the chat today - don't think they are having any luck with big pharma by the way kirk talked . just the way i heard it . Disappointed in christophe , thought he would bring more to the table . Great results today but there is

[Quentin30]

You're assuming: a) they can pay for the trial... if they go it alone, the dilution will at least halve the pps from here. b) they get approval before the key patents expire in 2027 - the hope is that after starting this trial in Q2 2025, mid trial results are enough to obtain accelerated approval... the phase III then just confirms data whilst they sell product. with b) how long will it

[spesestsemper]

You are always paying a premium for the future in stocks . The question becomes , how big a premium are you willing to pay for something that is still a ways out . I think its not unreasonable for the share price to be hiigher than it sits today . I still maintain that an outright sale is to the benefit of everyone . I can see big pharma being interested in the company at a reasonable valution

[Noteable]

Repeatedly having to be restated - ONCY'S  patents do nor run out until 2031 and an FDA approval would grant pelareorep 13 years of exclusivity from the date of approval for each indication the pelareorep is granted. The rest of the stuff is just a disquieting rant by someone who doesn't own any shares in the company.

[Noteable]

Demand is hot for big results in key markets like mBC with an unmet treatment need. As for Big Pharma, the emphasis now is on finding therapies that have been de-risked with human data, as ONCY has been demonstrating over time, and as had been accomplished and reported on today in HR+/HER2- Breast Cancer.   Analysis shows that around 122,000 HR+/HER2- mBC patients will be ready for

[Noteable]

Now for the real facts ... Demand is hot for big results in key markets like mBC with an unmet treatment need. As for Big Pharma, the emphasis now is on finding therapies that have been de-risked with human data, as ONCY has been demonstrating over time, and as had been accomplished and reported on today in HR+/HER2- Breast Cancer.   Analysis shows that around 122,000 HR+/HER2- mBC

[Quentin30]

I just listened to today's Cantor fireside chat... Nice to hear that they are aiming for AA, but this il be from data from  the next trial, as I have been saying. What surprised me, was that for once, Kirk actually presented some realisic timeline... they aim to seek approval in 3-5 years... that is a very long way to go before any inflection point. when they say 3-5 years, that was not

[Noteable]

Kirk Look said nothing about a tineline of 3-5 years. It's all in your vivid imagination Quentin30 Koffey. 

[Noteable]

And now that Quentin30 has admitted he doesn't own she's in ONCY, perhaps now he will stop posting his imaginary visions and hearings  here.

[Noteable]

Should read : Quentin30 has admitted he doesn't own shares in ONCY, 

[Quentin30]

For three years now, you have been posting ad nauseum, and suggesting that ONCY is worth tens of billions... and yet the pps is down in all the time you've been posting... I have clearly stated I am out... I was invested for 20 years... I see nothing worthwhile for another 2 - there are better places for my money.. IN two years, you'll still be here with the rest of the hopefuls.... 

[Azzak34]

If you're out there's no need to continue to post your opinions here. Yoube demonstrated over and over that you are incapable of understanding stocks and their value/potential. 

[Quentin30]

Oh, excuse me Azzak, I didn't realise that only shareholders were allowed to post here... but thanks to your comment, I think I will continue posting as much as I see fit.. It might just help some would be investors avoid pouring their money down the bowl. Just think, if you'd sold out when I did last October/Nov., you could have got out with a doubling... your entry point is justt= over

[Buckhenry]

Ole azzwhole et al woke pumpers are real pieces of work. BTW... when is dilution and RS starting???

[Azzak34]

What's woke got to do with anything? Is calling people woke the new Mccarthy hearings tactic? How many domestic animals have been consumed near you? 

[inthno]

At 2:40 of the Cantor fireside Kirk look states, we sit here we these 2 concepts and we hope to put them into place in the next 3-5 years. Clearly stated for all to hear.

[inthno]

At 3:35  of the presentation Kirk also states at 3-5 we will be well on our way into enrolling patients into both studies. Keep listening as Kirk then states that in 5 years if the data proves out that they will be submitting for approval in either 1 or both of the indications. Noteable, did you even listen to the presentation as it clearly stated the timelines that they are hoping for and

[inthno]

At 3:35  of the presentation Kirk also states at 3-5 we will be well on our way into enrolling patients into both studies. Keep listening as Kirk then states that in 5 years if the data proves out that they will be submitting for approval in either 1 or both of the indications. Noteable, did you even listen to the presentation as it clearly stated the timelines that they are hoping for and

[inthno]

Starting at about 22 minutes into the presentation Kirk states that they are powering the study to have a readout at about 2 years at which time if the data presents as they hope to then apply for AA. But first they need to get the trial approved and up and running.

[13X2413]

Surprising quiet from the pumpers about this info. They're chatting amongst themselves as we speak. I can hear them now......" Oh oh, what do we do now?!"

[CMHarring218431]

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs 9:00 AM ET 9/20/24 | GlobeNewswire Related Quotes   4:00 PM ET 9/19/24 Symbol Last % Chg